Vhio

• A recent study in *JCO Precision Oncology* shows that combining the VIGex gene expression signature with circulating tumor DNA (ctDNA) analysis may enhance immunotherapy response prediction. • The VIGex signature classifies the tumor microenvironment's inflammatory status, with the VIGex-Hot subgroup showing better survival rates in patients treated with pembrolizumab. • Combining VIGex classification with ctDNA dynamics improves the prediction of response to immunotherapy, indicating greater clinical benefit in VIGex-Hot tumors with decreased ctDNA levels. • A phase III clinical trial is planned to prospectively validate the clinical utility of VIGex and ctDNA dynamics for patient selection and treatment strategies.

VIGex and ctDNA Analysis Improves Immunotherapy Response Prediction in Solid Tumors